Molbio Diagnostics IPO Day 3 Final Subscription Status: 70.26x Subscribed; GMP at ₹149
The Molbio Diagnostics IPO Day 3 final subscription status stood at 70.26 times after bidding closed on 12 August 2026. Qualified Institutional Buyers led demand at 186.39x, while the issue also received double-digit subscription from other major categories. Its latest Grey Market Premium (GMP) is ₹149, implying an indicative price of ₹956 against the upper issue price of ₹807.
| Metric | Final update |
| Bidding day | Day 3, Closing Day |
| Data status | Final after close on 12 August 2026 |
| Overall subscription | 70.26x |
| Qualified Institutional Buyers | 186.39x |
| Non-Institutional Investors | 49.80x |
| Retail investors | 12.98x |
| Employee category | 13.28x |
| Current GMP | ₹149 |
| GMP percentage | 18.5% |
| Indicative price | ₹956 |
| Closing date | 12 August 2026 |
Molbio Diagnostics IPO Day 3 Final Subscription Status
Molbio Diagnostics received bids equivalent to 70.26 times the shares offered by the end of the three-day bidding period.
Qualified Institutional Buyers (QIBs) recorded the highest final subscription at 186.39x. Non-Institutional Investors (NIIs) followed at 49.80x. Retail demand closed at 12.98x, while the employee portion was subscribed 13.28x.
| Investor category | Day 2 close | Day 3 Final | Change |
| QIBs | 1.39x | 186.39x | +185.00x |
| NIIs | 5.21x | 49.80x | +44.59x |
| Retail investors | 3.18x | 12.98x | +9.80x |
| Employees | 4.78x | 13.28x | +8.50x |
| Overall | 3.11x | 70.26x | +67.15x |
The final-day acceleration was overwhelmingly driven by institutional bidding. However, demand was not confined to QIBs. Retail, NII, and employee portions also ended well above their respective reserved share quantities.
Subscription multiples measure the number of shares bid for relative to shares available in each category. They do not represent the number of unique applicants.
Final Day-wise Subscription Trend
The IPO moved from below full subscription on Day 1 to 3.11x on Day 2, before institutional bids sharply increased the overall multiple on the final day.
| Bidding stage | Overall subscription | Leading category |
| Day 1 close | 0.34x | QIBs, 0.63x |
| Day 2 close | 3.11x | NIIs, 5.21x |
| Day 3 Final | 70.26x | QIBs, 186.39x |
The change in leadership is notable. QIBs led the opening day, NIIs had the highest multiple after Day 2, and QIB demand then expanded sharply at the final close. Retail participation also strengthened from 3.18x on Day 2 to 12.98x finally.
Molbio Diagnostics IPO GMP Today and Estimated Listing Price
The latest available Molbio Diagnostics IPO GMP is ₹149 as of the evening (6:30 p.m. to 8:29 p.m. IST) on 12 August 2026. The previous available reading was ₹138 on 11 August, meaning the premium increased by ₹11.
At the upper price band of ₹807:
Indicative price = ₹807 + ₹149 = ₹956
GMP percentage = ₹149 ÷ ₹807 × 100 = approximately 18.5%
The ₹956 figure is only an indicative grey-market calculation. GMP operates in an unofficial and unregulated market, can change quickly before listing, and does not guarantee either the opening price or a listing gain.
What Stands Out in Today’s Bidding
Two points are particularly visible in the final data.
First, institutional participation was the main driver of the closing-day increase. The QIB multiple jumped from 1.39x after Day 2 to 186.39x finally. Second, demand became broad-based by the close, with each reported public investor category reaching a double-digit multiple.
There are also important limitations. Category subscription levels are influenced by the number of shares reserved for each group, so multiples should not be compared without considering allocation sizes. Moreover, high subscription does not establish fair valuation, business quality, or future returns.
Subscription and GMP also rose at very different speeds. Overall demand climbed from 3.11x to 70.26x between Day 2 and the final close, while GMP moved from ₹138 to ₹149. They measure different forms of demand, so their magnitude need not move together.
IPO Details Retail Investors Need
| Detail | Molbio Diagnostics IPO |
| Price band | ₹768 to ₹807 per share |
| Lot size | 18 shares |
| Minimum retail investment | ₹14,526 at ₹807 |
| Total issue size | About ₹939.70 crore |
| Fresh issue | ₹200 crore |
| Offer for Sale (OFS) | About ₹739.70 crore |
| Issue type | Book-built mainboard IPO |
| Closing date | 12 August 2026 |
| Expected listing date | 17 August 2026 |
| Exchange | BSE and NSE |
The issue included both a fresh issue and an OFS. Proceeds from the OFS go to selling shareholders rather than the company.
Brief Company and Financial Context
Molbio Diagnostics develops point-of-care diagnostic systems, led by its portable Truenat molecular-testing platform. Test kits are the company’s largest revenue driver, contributing about 74% of product sales in FY2026. For the year ended 31 March 2026, the company reported consolidated sales of about ₹1,445.69 crore and net profit of ₹166.59 crore.
Fresh-issue proceeds are intended for research and development infrastructure, a Centre of Excellence, plant and equipment at manufacturing facilities, and general corporate purposes. Investors should also consider customer-concentration risk, as dependence on a limited group of large customers can affect revenue if procurement patterns change.
What Happens Next
With bidding complete, the focus now shifts to allotment and listing. The basis of allotment is expected on 13 August 2026, followed by refund or fund-unblocking and demat-credit processes around 14 August 2026. Molbio Diagnostics shares are expected to list on the BSE and National Stock Exchange of India (NSE) on 17 August 2026.
Frequently Asked Questions (FAQs)
Q: How many times was the Molbio Diagnostics IPO subscribed on Day 3 Final?
A: The Molbio Diagnostics IPO closed with an overall subscription of 70.26x on Day 3. QIBs led at 186.39x, followed by NIIs at 49.80x, employees at 13.28x, and retail investors at 12.98x.
Q: What is the Molbio Diagnostics IPO GMP today?
A: The latest available Molbio Diagnostics IPO GMP is ₹149 as of the evening of 12 August 2026. GMP is an unofficial, unregulated market indicator and can change before the stock lists.
Q: What listing price does the current Molbio Diagnostics IPO GMP indicate?
A: With an upper issue price of ₹807 and a GMP of ₹149, the indicative price works out to approximately ₹956 per share. This is a grey-market estimate, not a guaranteed listing price.
Q: Does 70.26x subscription guarantee that Molbio Diagnostics will list at a premium?
A: No. A high subscription shows that bid demand exceeded the shares available, but it does not guarantee a premium listing. Market conditions, valuation, investor sentiment, and changes in GMP before listing can all influence the actual opening price.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
